Advanced breast cancer
Conditions
Interventions
Sponsors
Cancer Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years old, male or female; 2. Pathologic diagnosis of HER2-positive advanced breast cancer; 3. Before and after treatment, CT or MRI examination data should be available, which can be used to evaluate the tumor efficacy or the tumor efficacy record data evaluated by a doctor; 4. Subject has received prior pyrotinib therapy and progressed; 5. Subjects are treated with vedicitumab-based treatment regimen after progression of pyrotinib therapy; 6. Subjects voluntarily participate in the project.
Exclusion criteria
Exclusion criteria: 1. After the progression of pyrotinib therapy, he has received other systemic anti-tumor therapy modalities in the basic treatment with vedicitumab; 2. Other conditions in which the patient is not suitable for inclusion in the judgment of the clinician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;DCR;DOR;OS;Safety of vedicitumab for real-world treatment;Real-world medication patterns for vedicitumab; | — |
Countries
China
Contacts
Public ContactBinghe Xu
Cancer Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed